The incremental reductions in HbA1c observed with sacubitril/valsartan compared with valsartan in PARAGON-HF or with enalapril in PARADIGM-HF are small, but appear to be consistent across the spectrum of LVEF and to be sufficient to decrease the requirement for insulin. This evidence concerns the gene INS and hydrops fetalis.